News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
274,723 Results
Type
Article (18420)
Company Profile (169)
Press Release (256134)
Section
Business (73697)
Career Advice (131)
Deals (12548)
Drug Delivery (49)
Drug Development (56044)
Employer Resources (31)
FDA (8815)
Job Trends (6105)
News (147284)
Policy (12147)
Tag
Academia (1085)
Alliances (20417)
Alzheimer's disease (842)
Antibody-drug conjugate (ADC) (53)
Approvals (8750)
Artificial intelligence (58)
Bankruptcy (87)
Best Places to Work (5566)
Biotechnology (133)
Breast cancer (98)
Cancer (778)
Cardiovascular disease (58)
Career advice (114)
CAR-T (71)
Cell therapy (229)
Clinical research (45155)
Collaboration (228)
Compensation (87)
COVID-19 (1073)
C-suite (54)
Cystic fibrosis (71)
Data (696)
Diabetes (96)
Diagnostics (1739)
Earnings (27493)
Events (45482)
Executive appointments (160)
FDA (9129)
Funding (175)
Gene editing (53)
Gene therapy (169)
GLP-1 (433)
Government (1517)
Healthcare (8558)
Infectious disease (1107)
Inflammatory bowel disease (85)
IPO (6821)
Job creations (787)
Job search strategy (101)
Layoffs (189)
Legal (1387)
Lung cancer (142)
Manufacturing (100)
Medical device (4303)
Medtech (4306)
Mergers & acquisitions (5813)
Metabolic disorders (283)
Neuroscience (1039)
NextGen Class of 2024 (2390)
Non-profit (1373)
Northern California (810)
Obesity (167)
Opinion (82)
Parkinson's disease (61)
Patents (60)
People (21086)
Phase I (13962)
Phase II (20293)
Phase III (15302)
Pipeline (169)
Postmarket research (1598)
Preclinical (5341)
Press Release (64)
Radiopharmaceuticals (181)
Rare diseases (172)
Real estate (1568)
Regulatory (10047)
Research institute (1260)
Southern California (680)
Startups (1572)
United States (7152)
Vaccines (191)
Weight loss (126)
Date
Today (132)
Last 7 days (527)
Last 30 days (1869)
Last 365 days (22360)
2024 (18993)
2023 (23898)
2022 (28769)
2021 (30068)
2020 (25630)
2019 (19122)
2018 (14127)
2017 (15134)
2016 (13220)
2015 (15301)
2014 (10232)
2013 (7489)
2012 (7638)
2011 (7808)
2010 (7101)
Location
Africa (166)
Asia (16852)
Australia (2926)
California (1748)
Canada (535)
China (160)
Colorado (58)
Connecticut (81)
Europe (40410)
Florida (235)
Georgia (57)
Illinois (120)
Indiana (102)
Japan (48)
Maryland (280)
Massachusetts (1526)
Minnesota (138)
New Jersey (583)
New York (547)
North Carolina (429)
Northern California (810)
Ohio (83)
Pennsylvania (491)
South America (228)
Southern California (680)
Texas (223)
Washington State (241)
274,723 Results for "pep therapy".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Business
PEP-Therapy and Institut Curie Announce First Patients Dosed in Phase Ib Clinical Trial Evaluating PEP-010 in Ovarian and Pancreatic Cancers
PEP-Therapy, a clinical-stage biotechnology company developing first-in-class peptides as targeted therapies in oncology, and Institut Curie, France’s leading cancer center, announced the dosing of the first patients in a Phase Ib clinical trial evaluating PEP-Therapy’s lead candidate, PEP-010, based on highly encouraging Phase Ia results.
April 25, 2024
·
6 min read
Drug Development
RION Announces Initiation of Phase 2A Clinical Study for Purified Exosome Product™ (PEP™) in Diabetic Foot Ulcers
RION’s Phase 2A clinical trial focuses on evaluating the safety and efficacy of Platelet Exosome Product™ (PEP™) combined with TISSEEL fibrin sealant for treating Diabetic Foot Ulcers (DFU).
January 30, 2024
·
6 min read
Press Releases
MBX Biosciences Raises $63.5 Million in Series C Financing to Advance Precision Endocrine Peptide™ (PEP™) Platform
August 5, 2024
·
4 min read
Drug Development
RION Announces First Patient Dosed in Phase 2 Clinical Study of Purified Exosome Product™ for Diabetic Foot Ulcers
RION, a clinical-stage regenerative medicine company at the forefront of exosome therapeutics, announced today the first subject was dosed in the Phase 2 clinical trial with its novel product, known as Purified Exosome Product™ (PEP™).
May 7, 2024
·
5 min read
Press Releases
PepGen to Participate in Upcoming Investor Conferences
November 4, 2024
·
1 min read
Press Releases
KITHER BIOTECH ANNOUNCES PHASE 1 CLINICAL STUDY OF KIT2014, A NOVEL INHALED PEPTIDE THERAPY FOR CYSTIC FIBROSIS
October 30, 2024
·
3 min read
Editorial
Eyes, Ears Get Their Due With Cell and Gene Therapy
With promising early results, cell and gene therapies are making headway against both rare and common ocular and auditory diseases.
September 3, 2024
·
4 min read
·
Heather McKenzie
Press Releases
Abstract Describing Significant Results of Crofelemer for Cancer Therapy-Related Diarrhea in Breast Cancer Patients Accepted for Presentation at San Antonio Breast Cancer Symposium (SABCS)
November 4, 2024
·
6 min read
Drug development
5 Sickle Cell Therapies to Watch Following Pfizer’s Oxbryta Exit
In the wake of Pfizer’s voluntary market withdrawal of the popular sickle cell disease therapy,
BioSpace
looks at five investigational drugs currently making their way through the pipeline.
October 21, 2024
·
4 min read
·
Kate Goodwin
Business
PepGen Reports First Quarter 2024 Financial Results and Recent Corporate Highlights
PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases, today reported financial results and recent corporate highlights for the quarter ended March 31, 2024.
May 14, 2024
·
10 min read
1 of 27,473
Next